217972-87-7

Basic information

• Product Name: 1H-1,4-DIAZEPINE-1-CARBOXYLIC ACID, HEXAHYDRO-5-METHYL-, PHENYLMETHYL ESTER
• Synonyms: 1H-1,4-DIAZEPINE-1-CARBOXYLIC ACID, HEXAHYDRO-5-METHYL-, PHENYLMETHYL ESTER;Benzyl 5-Methyl-1,4-diazepane-1-carboxylate
• CAS NO: 217972-87-7
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.3208
• Mol File: 217972-87-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-1,4-DIAZEPINE-1-CARBOXYLIC ACID, HEXAHYDRO-5-METHYL-, PHENYLMETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-1,4-DIAZEPINE-1-CARBOXYLIC ACID, HEXAHYDRO-5-METHYL-, PHENYLMETHYL ESTER(217972-87-7)
• EPA Substance Registry System: 1H-1,4-DIAZEPINE-1-CARBOXYLIC ACID, HEXAHYDRO-5-METHYL-, PHENYLMETHYL ESTER(217972-87-7)

Safety Data

• Hazardous Substances Data: 217972-87-7(Hazardous Substances Data)

Usage

General Description

The chemical 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-methyl-, phenylmethyl ester, also known as phenylmethyl ester of clozapine, is a derivative of the antipsychotic medication clozapine. It is used for the treatment of mental disorders such as schizophrenia and bipolar disorder. 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-methyl-, phenylmethyl ester acts on several neurotransmitter receptors in the brain, including dopamine and serotonin receptors, to help regulate mood and behavior. The phenylmethyl ester form of clozapine is a prodrug, which means it is metabolized in the body to produce the active form of the medication. It is typically administered orally in tablet form and is associated with a range of potential side effects, including drowsiness, weight gain, and an increased risk of seizures.

Upstream product

• 501-53-1 benzyl chloroformate 
• 22777-05-5 hexahydro-5-methyl-1H-1,4-diazepine 
• 1030377-23-1 benzyl (2-((tert-butoxycarbonyl)amino)ethyl)(3-oxobutanoyl)carbamate 

Downstream Products

• 1001401-61-1 C₁₄H₂₀N₂O₂ 
• 1001401-60-0 benzyl (R)-5-methyl-1,4-diazepane-1-carboxylate 
• 1030377-24-2 1-benzyl 4-tert-butyl 5-methyl-1,4-diazepane-1,4-dicarboxylate 

Relevant articles and documents

PROCESS FOR THE RESOLUTION OF (R,S)-DIAZEPANE AND DIAZEPANONE DERIVATIVES

The present invention relates to a process for the preparation of an acid salt (T) of a compound of formula (A) (A) as well as to the acid salt (T) and the compound (A) as such,wherein R1 is selected from the group consisting of H, PG1 and RA, with RA being or and wherein PG1 is a suitable protecting group, and wherein n is 0 or 1, wherein the acid salt (T) is the salt of one stereoisomer of a chiral acid, preferably wherein the chiral acid salt is a tartaric acid derivative salt, preferably wherein the tartaric acid derivative salt is selected from the group consisting of 2,3-ditoluoyl tartaric acid salt, 2,3-dibenzoyl tartaric acid salt, 2,3-dianisoyl tartaric acid salt, 2,3-dibenzoyl tartaric acid mono(dimethylamide) salt and a mixture of two or more thereof. Further the present invention relates to use of (T) and/or (A) for the preparation of suvorexant.

Substituted diazepan orexin receptor antagonists

The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.